Stage II Seminoma: Why Chemotherapy Should Remain a Standard.
Eur Urol Open Sci
; 49: 69-70, 2023 Mar.
Article
en En
| MEDLINE
| ID: mdl-36793752
ABSTRACT
Chemotherapy (three cycles of bleomycin + etoposide + cisplatin or four of etoposide + cisplatin) cures the vast majority of stage II seminomas. Retroperitoneal lymph node dissection (RPLND) is safe in early-stage seminoma, but the risk of relapse is not negligible. Long-term chemotherapy side effects are a reality but may be reduced using de-escalation strategies such as in the SEMITEP trial design, motivated by growing interest in survivorship. RPLND may be an option for well-informed select patients who understand that it may be associated with a higher rate of relapse than with cisplatin-based chemotherapy. In any case, local and systemic treatment should not be performed outside high-volume centers.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Eur Urol Open Sci
Año:
2023
Tipo del documento:
Article
País de afiliación:
Francia